Compare LODE & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | TARA |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 45 | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 292.9M |
| IPO Year | 2004 | 2014 |
| Metric | LODE | TARA |
|---|---|---|
| Price | $3.85 | $4.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.00 | ★ $24.40 |
| AVG Volume (30 Days) | ★ 1.2M | 621.2K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $2,948,000.00 |
| Revenue This Year | $1,582.85 | N/A |
| Revenue Next Year | $246.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $2.77 |
| 52 Week High | $4.80 | $7.82 |
| Indicator | LODE | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 35.24 |
| Support Level | $3.41 | $4.11 |
| Resistance Level | $4.12 | $5.53 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 95.36 | 12.13 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.